DISEASE CHARACTERISTICS:

Inclusion criteria:

• Pathologically confirmed ovarian epithelial cancer, peritoneal serous cancer, or fallopian tube cancer

  • Patient's disease recurrence or progression occurs between 0 to 12 months (1 to 356 days) from prior platinum-containing chemotherapy regimen

• Patient may have received up to three prior chemotherapy regimens for the treatment of this malignancy

  • Patients who may have received prior treatment with paclitaxel and/or a platinum compound will be allowed
  • Rechallenge with the same platinum-based regimen is considered 1 prior regimen
  • Patients who have been treated with consolidation treatment are allowed and the consolidation will not be considered a separate regimen
  • Hormonal therapy (i.e. progesterones, estrogens, anti-estrogens, aromatase inhibitors) will not be considered a prior chemotherapy regimen

• Measurable or evaluable disease either by the GOG Response Evaluation Criteria in Solid Tumors (RECIST) or CA 125 criteria

  • RECIST Criteria - Patients must have at least one lesion that can be accurately measured in at least one dimension with longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm with spiral CT scan

    • If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology

  • CA 125 Criteria - CA 125 ≥ 70 on two occasions at least one week apart

    • Subject must not have received any mouse antibodies in the past and must be at least 28 days from major surgery prior to evaluation of CA 125

Exclusion criteria:

• Presence of central nervous system or brain metastases

PATIENT CHARACTERISTICS:

Inclusion criteria:

• ECOG performance status ≤ 2
• Absolute neutrophil count ≥ 1,500/mm³
• Hemoglobin ≥ 8.0 g/dL (transfusions allowed)
• Platelet count ≥ 100,000/mm³
• Total bilirubin ≤ upper limit of normal (ULN)

• AST and ALT and alkaline phosphatase must be within the following range:

  • AST or ALT normal AND alkaline phosphatase ≤ 5 times ULN
  • AST or ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN
  • AST or ALT ≤ 5 times ULN AND alkaline phosphatase normal
• Negative pregnancy test
• Patients of childbearing potential must be willing to consent to using effective contraception while on treatment and for three months following the completion of treatment

Exclusion criteria:

• Peripheral neuropathy ≥ grade 2
• History of a severe hypersensitivity reaction to docetaxel, bevacizumab, or to other drugs formulated with polysorbate (Tween) 80
• Blood pressure of > 150/100 mm Hg
• Unstable angina
• New York Heart Association (NYHA) Grade II or greater congestive heart failure
• History of myocardial infarction within 6 months
• History of stroke within 6 months
• Clinically significant peripheral vascular disease
• Evidence of bleeding diathesis or coagulopathy
• Significant traumatic injury within 28 days prior to Day 0
• Pregnant (positive pregnancy test) or lactating
• Urine protein:creatinine ratio ≥ 1.0
• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
• Serious, non-healing wound, ulcer, or bone fracture
• Evidence of malignancy in the last 5 years, other than non-melanoma cutaneous carcinomas
• History of hemoptysis (bright red blood of ½ teaspoon or more) within last 3 months
• Patients believed to possibly be at higher than average risk of perforation, including symptoms or findings of partial or complete bowel obstruction, history of fistula, patients requiring parenteral nutrition and hydration, and those with history of prior perforation due to tumor or perforation within last 6 months from other causes will be excluded from study

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

• At least 4 weeks since major surgery, with full recovery

• At least 3 weeks since radiotherapy, with full recovery

  • Measurable disease must be completely outside of the radiation port

Exclusion criteria:

• Prior treatment with docetaxel or bevacizumab
• Patients may not receive study drug until at least 28 days from prior chemotherapy
• Major surgical procedure or open biopsy within 28 days prior to Day 0
• Minor surgical procedures such as fine-needle aspirations or core biopsies within 7 days prior to Day 0

• Concurrent immunotherapy or hormonal therapy for the specific purpose of treatment for the ovarian cancer

  • Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to enrollment
  • Continuation of hormonal replacement therapy is allowed
• Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study
• Anticipation of need for major surgical procedure during the course of the study
• No concurrent irradiation of an indicator lesion
• No other concurrent chemotherapy or immunotherapy
• Also see Disease Characteristics